l 753037 has been researched along with thromboxane a2 in 1 studies
| Studies (l 753037) | Trials (l 753037) | Recent Studies (post-2010) (l 753037) | Studies (thromboxane a2) | Trials (thromboxane a2) | Recent Studies (post-2010) (thromboxane a2) |
|---|---|---|---|---|---|
| 18 | 1 | 1 | 5,617 | 224 | 429 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buie, PS; Krause, SM; Lynch, JJ; Ma, XL; Shen, YT | 1 |
1 other study(ies) available for l 753037 and thromboxane a2
| Article | Year |
|---|---|
Chronic therapy with an ET(A/B) receptor antagonist in conscious dogs during progression of congestive heart failure. Intracellular Ca(2+) regulation and nitric oxide mediated coronary relaxation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Analysis of Variance; Animals; Calcium; Cardiac Pacing, Artificial; Coronary Vessels; Dogs; Endothelin Receptor Antagonists; Heart Failure; In Vitro Techniques; Myocardial Contraction; Nitric Oxide; Pyridines; Receptor, Endothelin A; Receptor, Endothelin B; Sarcoplasmic Reticulum; Sodium Nitrite; Stroke Volume; Thromboxane A2; Vascular Resistance; Vasoconstriction | 2000 |